CTMX (CytomX Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CTMX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Alejandra Carvajal | Chief Legal Officer | A | — | — |
| 2026-07-30 | Charles S. Fuchs | Director | A | — | — |
| 2026-06-22 | Halley E Gilbert | Director | A | — | — |
| 2026-06-22 | James R Meyers | Director | A | — | — |
| 2026-06-22 | Matthew P. Young | Director | A | — | — |
| 2026-06-22 | Mani Mohindru | Director | A | — | — |
| 2026-06-22 | Alan Ashworth | Director | A | — | — |
| 2026-06-22 | Zhen Su | Director | A | — | — |
| 2026-06-22 | Elaine V Jones | Director | A | — | — |
| 2026-06-17 | Christopher Ogden | Chief Financial Officer | Sell | — | — |
| 2026-03-19 | Christopher Ogden | Chief Financial Officer | Sell | — | — |
| 2026-03-19 | Yu-Waye Chu | Chief Medical Officer | Sell | — | — |
| 2026-03-19 | Sean A. McCarthy | CEO | Sell | — | — |
| 2026-03-19 | MARCIA BELVIN | SVP, Chief Scientific Officer | Sell | — | — |
| 2026-02-04 | Christopher Ogden | Chief Financial Officer | A | — | — |
| 2026-02-04 | MARCIA BELVIN | SVP, Chief Scientific Officer | A | — | — |
| 2026-02-04 | Rachael Lester | Chief Business Officer | A | — | — |
| 2026-02-04 | Sean A. McCarthy | CEO | A | — | — |
| 2026-02-04 | Yu-Waye Chu | Chief Medical Officer | A | — | — |
| 2025-11-10 | Sean A. McCarthy | CEO | Sell | — | — |
| 2025-10-29 | Rachael Lester | Chief Business Officer | A | — | — |
| 2025-09-30 | Christopher Ogden | Chief Financial Officer | A | — | — |
| 2025-09-30 | MARCIA BELVIN | SVP, Chief Scientific Officer | A | — | — |
| 2025-09-30 | Sean A. McCarthy | CEO | A | — | — |
| 2025-09-30 | Yu-Waye Chu | Chief Medical Officer | A | — | — |
| 2025-06-17 | Sean A. McCarthy | CEO | MIXED | — | — |
| 2025-06-17 | Christopher Ogden | Chief Financial Officer | MIXED | — | — |
| 2025-06-17 | MARCIA BELVIN | SVP, Chief Scientific Officer | MIXED | — | — |
| 2025-06-13 | Mani Mohindru | Director | A | — | — |
| 2025-06-13 | Elaine V Jones | Director | A | — | — |
| 2025-06-13 | Alan Ashworth | Director | A | — | — |
| 2025-06-13 | Zhen Su | Director | A | — | — |
| 2025-06-13 | Halley E Gilbert | Director | A | — | — |
| 2025-06-13 | James R Meyers | Director | A | — | — |
| 2025-06-13 | Matthew P. Young | Director | A | — | — |
| 2025-03-20 | MARCIA BELVIN | SVP, Chief Scientific Officer | Sell | — | — |
| 2025-03-20 | Christopher Ogden | Chief Financial Officer | Sell | — | — |
| 2025-03-20 | Yu-Waye Chu | Chief Medical Officer | Sell | — | — |
| 2025-03-20 | LLOYD A ROWLAND | General Counsel | Sell | — | — |
| 2025-03-20 | Sean A. McCarthy | CEO | Sell | — | — |
| 2025-02-10 | MARCIA BELVIN | SVP, Chief Scientific Officer | A | — | — |
| 2025-02-06 | Christopher Ogden | Chief Financial Officer | A | — | — |
| 2025-02-06 | Yu-Waye Chu | Chief Medical Officer | A | — | — |
| 2025-02-06 | Sean A. McCarthy | CEO | A | — | — |
| 2025-02-06 | MARCIA BELVIN | SVP, Chief Scientific Officer | A | — | — |
| 2024-08-22 | Sean A. McCarthy | CEO | MIXED | — | — |
| 2024-08-22 | MARCIA BELVIN | SVP, Chief Scientific Officer | MIXED | — | — |
| 2024-08-22 | Christopher Ogden | Chief Financial Officer | MIXED | — | — |
| 2024-08-22 | LLOYD A ROWLAND | General Counsel | MIXED | — | — |
| 2024-08-22 | Jeffrey B Landau | Chief Business Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,201,767 | — |
| — | 10%+ Owner | 5,170,348 | — |
| — | 10%+ Owner | 4,349,864 | — |
| — | Director | 3,747,476 | — |
| — | Director | 3,244,829 | — |
| — | Director | 2,494,381 | — |
| — | CEO | 1,172,080 | — |
| — | 10%+ Owner | 749,055 | — |
| — | Director | 508,658 | — |
| — | — | 358,450 | — |
| — | SVP, Chief Scientific Officer | 300,760 | — |
| — | Chief Financial Officer | 295,324 | — |
| — | Chief Medical Officer | 189,446 | — |
| — | 10%+ Owner | 160,512 | — |
| — | Chief Business Officer | 123,556 | — |
| — | General Counsel | 120,594 | — |
| — | 10%+ Owner | 116,927 | — |
| — | Chief Legal Officer | 100,000 | — |
| — | 10%+ Owner | 74,293 | — |
| — | EVP, Chief Development Officer | 58,433 | — |
| — | Chief Medical Officer | 46,394 | — |
| — | Chief Financial Officer | 38,224 | — |
| — | Chief Medical Officer | 37,500 | — |
| — | Chief Financial Officer | 22,769 | — |
| — | Chief Business Officer | 20,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CTMX quote page; the site-wide leaderboard is on the insider transactions hub.